Close Menu

BMS

The headline and this story have been updated to reflect that BMS and Lilly have submitted to the FDA retrospective analysis on Erbitux's efficacy in colorectal cancer patients with wild-type KRAS mutations, which the agency may use to update the drug label.

By Adam Bonislawski
Two papers published in the current edition of Nature Biotechnology add significantly to the publicly available data on the specificity of kinase inhibitors.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Bristol Myers-Squibb and Saladax Biomedical today expanded an agreement covering companion diagnostics to include Johnson & Johnson's Ortho-Clinical Diagnostics.

Pages

The Centers for Disease Control and Prevention estimates more people get sick and die from drug-resistant germs than previously thought, the Washington Post reports.

According to the Associated Press, three universities and a healthcare institution are sharing a gift of $1 billion.

New rules seek to limit the type of scientific and medical research that can be used to guide public health regulations, the New York Times reports.

In Nature this week: FreeHi-C approach simulates Hi-C data from interacting genome fragments, and more.